Translational-Omics in Aortic Stenosis (TOmAS) Biobank
McGill University Health Centre/Research Institute of the McGill University Health Centre
10,000 participants
Oct 12, 2017
OBSERVATIONAL
Conditions
Summary
The objective of the TOmAS Biobank is the conservation of biological material (plasma, saliva, and tissue explanted during surgery), genetic material (DNA, RNA, etc.), and clinical data ("material/data") collected from patients with cardiovascular diseases (CVD) as well as from control participants, in order to allow future studies evaluating novel proteomic, transcriptomic and epigenomic markers (as well as other emerging -omic technologies) for CVD (i.e. aortic stenosis, cardiomyopathy, myorcardial infarction, etc). The study of physiological and genetic factors will allow for the discovery of new genomic and other -omic (including proteomic, transcriptomic and epigenomic) biomarkers associated with CVD which will lead to an improved understanding of the underlying biology of CVD and may provide future insights into the prevention and treatment of this type of disease.
Eligibility
Inclusion Criteria2
- CVD diagnosis including, but not limited to: Aortic Stenosis, Coronary Heart Disease, Heart Failure, Atrial Fibrilation, Dilated Cardiomyopathy, Myocardial Infarction, and Spontaneous Coronary Artery Dissection.
- Undergoing cardiac surgery for non-aortic valve pathology
Exclusion Criteria1
- Individuals with Congenital heart disease will be excluded
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
TOmAS is a biobank and all patients will be genotyped
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05930899